Recent Updates — BMEA

Biomea Fusion announced top-line results from its Phase 1 GLP-131 clinical trial for BMF-650, an investigational oral small-molecule glucagon-like peptide-1 receptor agonist. In the multiple ascending dose cohorts, mean weight reduction ranged from 1.5% to 3.2% at Day 29 compared with 0.1% for pooled placebo. The highest dosing cohort achieved a 6.1% mean weight reduction over four weeks using a rapid one-step titration to 400 mg daily. All treatment-emergent adverse events were mild or moderate, with no serious events or discontinuations related to the drug. Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies for diabetes and obesity.

Biomea Fusion, Inc. updated the anticipated timing for topline results from its ongoing Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers, which are now expected in October 2026. Biomea Fusion, Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics.

Biomea Fusion reported a net loss of $8.3 million for the quarter ended June 30, 2026, compared to $20.7 million in the prior year period. The company held $35.2 million in cash and cash equivalents as of June 30, 2026, with a projected cash runway extending into the second quarter of 2027. Clinical updates include ongoing enrollment for Phase II trials COVALENT-211 and COVALENT-212 evaluating icovamenib in Type 2 diabetes, with data expected in early 2027. Initial weight reduction data from the Phase I BMF-650 obesity trial is anticipated in the third quarter of 2026. The company also initiated a research collaboration with the University of Leicester to evaluate icovamenib combined with semaglutide for obesity. Biomea Fusion operates as a clinical-stage biopharmaceutical company focused on developing therapies for diabetes and obesity.